NASDAQ : FBRX
Forte Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 76.99 USD (Aug 26, 2026, 4:00 PM EDT) · Market cap 1.94B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.94B |
| Enterprise Value | 1.74B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 21.23M |
| Shares Outstanding | 25.19M |
| Shares Change (YoY) | +148.66% |
| Shares Change (QoQ) | +33.36% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 72.95% |
| Float | 18.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.24 |
| P/TBV Ratio | 10.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.01 |
| Quick Ratio | 9.82 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -62.28% |
| Return on Assets (ROA) | -37.79% |
| Return on Invested Capital (ROIC) | -41.96% |
| Return on Capital Employed (ROCE) | -51.12% |
| Weighted Average Cost of Capital (WACC) | 18.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.82M |
| Employee Count | 23 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.60M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.64 |
| 52-Week Price Change | +580.42% |
| 50-Day Moving Average | 52.74 |
| 200-Day Moving Average | 32.22 |
| Relative Strength Index (RSI) | 84.43 |
| Average Volume (20 Days) | 1,564,047 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.63M |
| Short Previous Month | 1.90M |
| Short % of Shares Out | 6.48% |
| Short % of Float | 8.68% |
| Short Ratio (days to cover) | 0.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -94.80M |
| Pretax Income | -86.33M |
| Net Income | -87.94M |
| EBITDA | -94.72M |
| EBIT | -94.80M |
| Earnings Per Share (EPS) | -$4.55 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 198.46M |
| Total Debt | n/a |
| Net Cash | 198.46M |
| Net Cash Per Share | $7.88 |
| Equity (Book Value) | 183.79M |
| Book Value Per Share | 7.52 |
| Working Capital | 182.81M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -71.98M |
| Capital Expenditures | -55,000 |
| Depreciation & Amortization | 75,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -72.03M |
| FCF Per Share | -$2.86 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -148.66% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.54% |
| FCF Yield | -3.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $73.80 |
| Price Target Difference | -4.14% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 28, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |